- September 28, 2021– Three Abstracts, Including One Late-Breaker, to be Presented on IMU-838, the Company’s Selective Oral DHODH Inhibitor, at the 37th…
- September 22, 2021– Preclinical Combination Data Suggests Extra-Ordinary Synergy Between Certain DHODH Inhibitors and Nucleoside Analogues – – Combination of IMU-838 and…
- September 8, 2021NEW YORK, September 8, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- August 6, 2021– Received FDA Clearance to Initiate Twin IMU-838 Phase 3 ENSURE Trials in Relapsing-Remitting Multiple Sclerosis and Supportive Phase 2…
- August 3, 2021NEW YORK, August 3, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
- July 19, 2021NEW YORK, July 19, 2021 – Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective…
- July 15, 2021NEW YORK, July 15, 2021 – Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective…
- July 14, 2021NEW YORK, July 14, 2021 – Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective…
- July 12, 2021– IMU-935 Has Been Observed In Vitro to Inhibit the Generation of Th17 Cells and Production of IL-17 Cytokines Without…
- July 1, 2021– Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838…
